Wanbury Share Price
Sector: Biotechnology & Drugs
You have to be logged in to add this to Watchlist.
Login or Register
211.00 -11.00 (-4.95%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
211
Today’s High
222.45
52 Week Low
91
52 Week High
291
214.00 -10.54 (-4.69%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
213.31
Today’s High
223.85
52 Week Low
91
52 Week High
290.2
Wanbury Analysis
Risk Meter
- 51% Low risk
- 51% Moderate risk
- 51% Balanced Risk
- 51% High risk
- 51% Extreme risk
Wanbury News
Wanbury Q3 FY24 results: profit at ₹10.27Cr, Revenue increased by 15.68% YoY
1 min read . 27 Jan 2024Wanbury Financials
- INCOME
- BALANCE SHEET
- Cashflow
- Period
- 2024
- Total Revenue
- 575.65
- Selling/ General/ Admin Expenses Total
- 86.92
- Depreciation/ Amortization
- 13.03
- Other Operating Expenses Total
- 116.09
- Total Operating Expense
- 493.12
- Operating Income
- 82.53
- Net Income Before Taxes
- 56.34
- Net Income
- 55.96
- Diluted Normalized EPS
- 9.34
- Period
- 2024
- Total Assets
- 343.49
- Total Liabilities
- 315.55
- Total Equity
- 27.94
- Tangible Book Valueper Share Common Eq
- 8.45
- Period
- 2024
- Cashfrom Operating Activities
- 3.98
- Cashfrom Investing Activities
- -16.63
- Cashfrom Financing Activities
- 14.55
- Net Changein Cash
- 1.91
- Period
- 2023
- Total Revenue
- 499.65
- Selling/ General/ Admin Expenses Total
- 86.86
- Depreciation/ Amortization
- 12.38
- Other Operating Expenses Total
- 65.71
- Total Operating Expense
- 488.72
- Operating Income
- 10.93
- Net Income Before Taxes
- -10.29
- Net Income
- -10.4
- Diluted Normalized EPS
- -3.05
- Period
- 2023
- Total Assets
- 303.87
- Total Liabilities
- 336.69
- Total Equity
- -32.82
- Tangible Book Valueper Share Common Eq
- -10.06
- Period
- 2023
- Cashfrom Operating Activities
- 19.8
- Cashfrom Investing Activities
- -8.84
- Cashfrom Financing Activities
- -31.99
- Net Changein Cash
- -21.03
- Period
- 2022
- Total Revenue
- 511.19
- Selling/ General/ Admin Expenses Total
- 74.81
- Depreciation/ Amortization
- 11.45
- Other Operating Expenses Total
- 100.77
- Total Operating Expense
- 410.96
- Operating Income
- 100.23
- Net Income Before Taxes
- 81.13
- Net Income
- 81.47
- Diluted Normalized EPS
- 9.85
- Period
- 2022
- Total Assets
- 352.55
- Total Liabilities
- 375.97
- Total Equity
- -23.42
- Tangible Book Valueper Share Common Eq
- -7.2
- Period
- 2022
- Cashfrom Operating Activities
- 40.52
- Cashfrom Investing Activities
- 0.59
- Cashfrom Financing Activities
- -28.58
- Net Changein Cash
- 12.52
- Period
- 2021
- Total Revenue
- 392.52
- Selling/ General/ Admin Expenses Total
- 64.15
- Depreciation/ Amortization
- 9.75
- Other Operating Expenses Total
- 93.2
- Total Operating Expense
- 384.25
- Operating Income
- 8.27
- Net Income Before Taxes
- -12.41
- Net Income
- -12.61
- Diluted Normalized EPS
- -5.04
- Period
- 2021
- Total Assets
- 289.18
- Total Liabilities
- 445.42
- Total Equity
- -156.24
- Tangible Book Valueper Share Common Eq
- -62.55
- Period
- 2021
- Cashfrom Operating Activities
- 16.68
- Cashfrom Investing Activities
- 8.04
- Cashfrom Financing Activities
- -17.39
- Net Changein Cash
- 7.34
- Period
- 2020
- Total Revenue
- 367.45
- Selling/ General/ Admin Expenses Total
- 67.48
- Depreciation/ Amortization
- 9.68
- Other Operating Expenses Total
- 100.79
- Total Operating Expense
- 353.69
- Operating Income
- 13.76
- Net Income Before Taxes
- 64.67
- Net Income
- 64.46
- Diluted Normalized EPS
- 4.46
- Period
- 2020
- Total Assets
- 278.69
- Total Liabilities
- 422.15
- Total Equity
- -143.45
- Tangible Book Valueper Share Common Eq
- -57.56
- Period
- 2020
- Cashfrom Operating Activities
- 44.13
- Cashfrom Investing Activities
- 63.66
- Cashfrom Financing Activities
- -107.87
- Net Changein Cash
- -0.08
- Period
- 2019
- Total Revenue
- 391.37
- Selling/ General/ Admin Expenses Total
- 75.89
- Depreciation/ Amortization
- 9.97
- Other Operating Expenses Total
- 103.4
- Total Operating Expense
- 385.46
- Operating Income
- 5.91
- Net Income Before Taxes
- -24.98
- Net Income
- -24.85
- Diluted Normalized EPS
- -10.38
- Period
- 2019
- Total Assets
- 286.05
- Total Liabilities
- 495.32
- Total Equity
- -209.28
- Tangible Book Valueper Share Common Eq
- -88.47
- Period
- 2019
- Cashfrom Operating Activities
- 29.73
- Cashfrom Investing Activities
- -3.07
- Cashfrom Financing Activities
- -26.78
- Net Changein Cash
- -0.13
- Period
- 2018
- Total Revenue
- 374.17
- Selling/ General/ Admin Expenses Total
- 87.32
- Depreciation/ Amortization
- 10.3
- Other Operating Expenses Total
- 180
- Total Operating Expense
- 451.72
- Operating Income
- -77.54
- Net Income Before Taxes
- -32.39
- Net Income
- -32.01
- Diluted Normalized EPS
- -13.43
- Period
- 2018
- Total Assets
- 272.72
- Total Liabilities
- 457.4
- Total Equity
- -184.68
- Tangible Book Valueper Share Common Eq
- -78.19
- Period
- 2018
- Cashfrom Operating Activities
- 32.49
- Cashfrom Investing Activities
- -1.39
- Cashfrom Financing Activities
- -33.26
- Net Changein Cash
- -2.16
- Period
- 2024-09-30
- Total Revenue
- 161.19
- Selling/ General/ Admin Expenses Total
- 26.35
- Depreciation/ Amortization
- 3.32
- Other Operating Expenses Total
- 32.81
- Total Operating Expense
- 144.51
- Operating Income
- 16.68
- Net Income Before Taxes
- 8.17
- Net Income
- 8.02
- Diluted Normalized EPS
- 2.45
- Period
- 2024-09-30
- Total Assets
- 396.78
- Total Liabilities
- 358.03
- Total Equity
- 38.75
- Tangible Book Valueper Share Common Eq
- 11.75
- Period
- 2024-09-30
- Cashfrom Operating Activities
- -18.57
- Cashfrom Investing Activities
- -25.59
- Cashfrom Financing Activities
- 46.65
- Net Changein Cash
- 2.49
- Period
- 2024-06-30
- Total Revenue
- 131.11
- Selling/ General/ Admin Expenses Total
- 25.15
- Depreciation/ Amortization
- 3.29
- Other Operating Expenses Total
- 28.73
- Total Operating Expense
- 123.42
- Operating Income
- 7.69
- Net Income Before Taxes
- 1.04
- Net Income
- 1.04
- Diluted Normalized EPS
- 0.31
- Period
- 2024-06-30
- Period
- 2024-06-30
- Period
- 2024-03-31
- Total Revenue
- 139.41
- Selling/ General/ Admin Expenses Total
- 20.14
- Depreciation/ Amortization
- 3.28
- Other Operating Expenses Total
- 30.68
- Total Operating Expense
- 98.96
- Operating Income
- 40.44
- Net Income Before Taxes
- 33.91
- Net Income
- 33.63
- Diluted Normalized EPS
- 2.53
- Period
- 2024-03-31
- Total Assets
- 343.49
- Total Liabilities
- 315.55
- Total Equity
- 27.94
- Tangible Book Valueper Share Common Eq
- 8.45
- Period
- 2024-03-31
- Cashfrom Operating Activities
- 3.98
- Cashfrom Investing Activities
- -16.63
- Cashfrom Financing Activities
- 14.55
- Net Changein Cash
- 1.91
- Period
- 2023-12-31
- Total Revenue
- 145.5
- Selling/ General/ Admin Expenses Total
- 24.63
- Depreciation/ Amortization
- 3.32
- Other Operating Expenses Total
- 28.89
- Total Operating Expense
- 127.67
- Operating Income
- 17.82
- Net Income Before Taxes
- 10.26
- Net Income
- 10.27
- Diluted Normalized EPS
- 3.13
- Period
- 2023-12-31
- Period
- 2023-12-31
- Period
- 2023-09-30
- Total Revenue
- 144.46
- Selling/ General/ Admin Expenses Total
- 21.07
- Depreciation/ Amortization
- 3.24
- Other Operating Expenses Total
- 29.69
- Total Operating Expense
- 130.36
- Operating Income
- 14.1
- Net Income Before Taxes
- 7.19
- Net Income
- 7.36
- Diluted Normalized EPS
- 2.25
- Period
- 2023-09-30
- Total Assets
- 346.21
- Total Liabilities
- 368.47
- Total Equity
- -22.26
- Tangible Book Valueper Share Common Eq
- -6.82
- Period
- 2023-09-30
- Cashfrom Operating Activities
- -6.68
- Cashfrom Investing Activities
- -11.84
- Cashfrom Financing Activities
- 24.25
- Net Changein Cash
- 5.73
- Period
- 2023-06-30
- Total Revenue
- 146.29
- Selling/ General/ Admin Expenses Total
- 21.08
- Depreciation/ Amortization
- 3.18
- Other Operating Expenses Total
- 26.83
- Total Operating Expense
- 136.12
- Operating Income
- 10.16
- Net Income Before Taxes
- 4.99
- Net Income
- 4.69
- Diluted Normalized EPS
- 1.43
- Period
- 2023-06-30
- Period
- 2023-06-30
- Period
- 2023-03-31
- Total Revenue
- 132.98
- Selling/ General/ Admin Expenses Total
- 20.7
- Depreciation/ Amortization
- 3.07
- Other Operating Expenses Total
- 23.82
- Total Operating Expense
- 122.48
- Operating Income
- 10.5
- Net Income Before Taxes
- 0.92
- Net Income
- 1.02
- Diluted Normalized EPS
- 0.43
- Period
- 2023-03-31
- Total Assets
- 303.87
- Total Liabilities
- 336.69
- Total Equity
- -32.82
- Tangible Book Valueper Share Common Eq
- -10.06
- Period
- 2023-03-31
- Cashfrom Operating Activities
- 19.8
- Cashfrom Investing Activities
- -8.84
- Cashfrom Financing Activities
- -31.99
- Net Changein Cash
- -21.03
- Period
- 2022-12-31
- Total Revenue
- 125.78
- Selling/ General/ Admin Expenses Total
- 19.17
- Depreciation/ Amortization
- 3.13
- Other Operating Expenses Total
- 23.78
- Total Operating Expense
- 122.45
- Operating Income
- 3.33
- Net Income Before Taxes
- -3.04
- Net Income
- -3.28
- Diluted Normalized EPS
- -1
- Period
- 2022-12-31
- Period
- 2022-12-31
Forecast
Income Sheet (In Cr)
Net Income Vs Revenue
Returns Metrics (In Cr)
ROA Vs ROE
Forecast
Balance Sheet
Asset vs Liability
Forecast
Cash Flow
Operating vs Investing
Wanbury Technical
Moving Average
SMA
- 5 Day233.87
- 10 Day242.32
- 20 Day235.07
- 50 Day246.2
- 100 Day220.44
- 300 Day187.55
Wanbury Peers
- Price
- Ratio
- Name
- Latest Price
- Change
- % Change
- 52W High
- 52W Low
- Mkt. Cap
- Shree Ganesh Remedies
- 671
- -27.9
- -3.99
- 950.05
- 557.95
- 862.05
- Nectar Lifesciences
- 34.2
- -0.69
- -1.98
- 56.39
- 25.02
- 766.97
- Wanbury
- 211
- -11
- -4.95
- 291
- 91
- 690.93
- Albert David
- 1296
- 0.4
- 0.03
- 1752.95
- 912.1
- 739.65
- Titan Biotech
- 757
- -11.7
- -1.52
- 1017.85
- 375
- 625.56
- Name
- P/E (X)
- P/B (X)
- ROE %
- OPM
- Shree Ganesh Remedies
- 31.28
- 7.35
- 24.29
- 19.73
- Nectar Lifesciences
- 157.05
- 0.73
- -0.65
- -0.41
- Wanbury
- 24.51
- 26.31
- -
- 7.62
- Albert David
- 9.67
- 1.92
- 13.89
- 11.87
- Titan Biotech
- 25.56
- 4.76
- 28.11
- 16.21
Wanbury Shareholding
Shareholding Pattern
*Promoter pledging: 30.52%
Shareholding Trend
Shareholding(%) v/s Date
Corporate Actions
- Board Meeting
- AGM
- Dividends
- Bonus
- Split
- Rights
- Meeting Date
- Purpose
- 13-Nov-24
- Quarterly Results
- 12-Aug-24
- Quarterly Results
- 16-May-24
- Audited Results
- 24-Jan-24
- Quarterly Results
- 20-Oct-23
- Quarterly Results & Preferential issue
- 11-Aug-23
- Quarterly Results
- 09-Jun-23
- Audited Results
- 30-May-23
- Audited Results
- 14-Feb-23
- Quarterly Results
- 28-Nov-22
- Quarterly Results
- Meeting Date
- Announced on
- Purpose
- 27-Sept-24
- 17-Sept-24
- AGM
- 18-Nov-23
- 26-Oct-23
- EGM
- 27-Sept-23
- 18-Sept-23
- AGM
- 21-Aug-23
- 20-Jul-23
- EGM
- 28-Sept-22
- 22-Jun-22
- AGM
- 17-Mar-22
- 23-Feb-22
- EGM
- 20-Mar-21
- 23-Feb-21
- EGM